KURA ONCOLOGY, INC.

(KURA)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
18.17 USD   +5.58%
06/23KURA ONCOLOGY, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/26Kura Oncology to Participate in Three Upcoming Investor Conferences
AQ
05/04KURA ONCOLOGY : Q1 Earnings Snapshot
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Kura Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

05/04/2022 | 04:05pm EDT

Kura Oncology, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 32.45 million compared to USD 30.69 million a year ago. Basic loss per share from continuing operations was USD 0.49 compared to USD 0.46 a year ago. Diluted loss per share from continuing operations was USD 0.49 compared to USD 0.46 a year ago.


© S&P Capital IQ 2022
All news about KURA ONCOLOGY, INC.
06/23KURA ONCOLOGY, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/26Kura Oncology to Participate in Three Upcoming Investor Conferences
AQ
05/04KURA ONCOLOGY : Q1 Earnings Snapshot
AQ
05/04KURA ONCOLOGY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RE..
AQ
05/04TRANSCRIPT : Kura Oncology, Inc., Q1 2022 Earnings Call, May 04, 2022
CI
05/04Kura Oncology Reports First Quarter 2022 Financial Results
AQ
05/04Kura Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/27Kura Oncology to Report First Quarter 2022 Financial Results
AQ
04/08Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergenc..
AQ
04/08Kura Oncology, Inc. Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Em..
CI
More news
Analyst Recommendations on KURA ONCOLOGY, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -148 M - -
Net cash 2022 321 M - -
P/E ratio 2022 -8,27x
Yield 2022 -
Capitalization 1 211 M 1 211 M -
EV / Sales 2022 -
EV / Sales 2023 47,9x
Nbr of Employees 117
Free-Float 94,4%
Chart KURA ONCOLOGY, INC.
Duration : Period :
Kura Oncology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KURA ONCOLOGY, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 18,17 $
Average target price 35,88 $
Spread / Average Target 97,4%
EPS Revisions
Managers and Directors
Troy E. Wilson Chairman, President, CEO & Chief Financial Officer
Mollie Leoni Senior Vice President-Clinical Development
Stephen Dale Chief Medical Officer
Kathleen Ford Chief Operating Officer
Faheem Hasnain Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
KURA ONCOLOGY, INC.29.79%1 211
GILEAD SCIENCES, INC.-13.12%79 122
VERTEX PHARMACEUTICALS33.22%74 821
REGENERON PHARMACEUTICALS, INC.-3.01%65 993
WUXI APPTEC CO., LTD.-13.42%44 742
BIONTECH SE-48.01%32 574